- Bluejay Diagnostics, Inc. (BJDX) announced and closed a **$4.5 million private placement** on **October 10, 2025**.  **[1704287_0001213900-25-098281_ea026096501ex99-1_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea026096501ex99-2_bluejay.htm:0]** 
- The offering included the sale of **2,250,000 shares of common stock** (or pre-funded warrants) and **Series F warrants to purchase up to 4,500,000 shares of common stock** at a purchase price of **$2.00 per share**.  **[1704287_0001213900-25-098281_ea026096501ex99-1_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea026096501ex99-2_bluejay.htm:0]** 
- The Series F warrants have an exercise price of **$1.75 per share** and are exercisable immediately, expiring 5.5 years from issuance.  **[1704287_0001213900-25-098281_ea026096501ex99-1_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea026096501ex99-2_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea0260965-8k_bluejay.htm:1]** 
- The company received **approximately $4.0 million** in net proceeds, which will be allocated to funding FDA approval processes, research and development, and general working capital.  **[1704287_0001213900-25-098281_ea026096501ex99-1_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea026096501ex99-2_bluejay.htm:0]** **[1704287_0001213900-25-098281_ea0260965-8k_bluejay.htm:1]** 
- A resale registration statement covering **175,000 shares of common stock** and **6,755,000 shares of common stock** underlying warrants is expected to be filed by **October 24, 2025**.  **[1704287_0001213900-25-098281_ea0260965-8k_bluejay.htm:1]**

Bluejay Diagnostics Closes $4.5 Million Private Placement

- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) **closed a private placement** on **October 10, 2025**.  **[1704287_cae2e01531dd41f6bd7762c4d96eccc6_0]** 
- The offering generated **gross proceeds of $4.5 million**.  **[1704287_cae2e01531dd41f6bd7762c4d96eccc6_0]** 
- The placement involved the sale of **2,250,000 shares of common stock** (or pre-funded warrants) and **Series F warrants to purchase up to 4,500,000 shares of common stock** at a purchase price of **$2.00 per share**.  **[1704287_cae2e01531dd41f6bd7762c4d96eccc6_0]** 
- The **net proceeds** are intended to fund matters related to **FDA approval** (including clinical studies), **research and development activities**, and **general working capital needs**.  **[1704287_cae2e01531dd41f6bd7762c4d96eccc6_0]**

Bluejay Diagnostics Closes Private Placement

- Bluejay Diagnostics has entered into definitive agreements for a private placement to sell **2,250,000 shares of common stock** (or pre-funded warrants) and Series F warrants to purchase up to **4,500,000 shares of common stock**.  **[1704287_e703ce773597482d898434dae5511089_0]** 
- The offering is priced at **$2.00 per share** for the common stock (or pre-funded warrant) and accompanying warrants, with the Series F warrants having an exercise price of **$1.75 per share**.  **[1704287_e703ce773597482d898434dae5511089_0]** 
- The private placement is expected to generate **$4.5 million** in gross proceeds and is anticipated to close on or about **October 10, 2025**.  **[1704287_e703ce773597482d898434dae5511089_0]** 
- The company intends to use the net proceeds to fund matters related to obtaining **FDA approval**, other **research and development activities**, and for **general working capital needs**.  **[1704287_e703ce773597482d898434dae5511089_0]**

Bluejay Diagnostics Announces Private Placement

- **Bluejay Diagnostics (BJDX)** and SanyoSeiko Co., Ltd. **amended their Master Service and Supply Agreements** on **October 9, 2025**, to expand SanyoSeiko's role in commercializing Bluejay's Symphony platform.  **[1704287_6e8edf3b0bee4b42ba2b95cb0b72de87_0]** 
- SanyoSeiko will provide **end-to-end support** for the Symphony platform, including manufacturing redevelopment, raw material sourcing, contract manufacturing of analyzers and cartridges, fulfillment, and quality control.  **[1704287_6e8edf3b0bee4b42ba2b95cb0b72de87_0]** 
- This expanded partnership aims to **strengthen Bluejay's supply chain resilience**, secure high-quality production capacity, and advance readiness for broader clinical validation and market introduction of the Symphony platform.  **[1704287_6e8edf3b0bee4b42ba2b95cb0b72de87_0]** 
- The Symphony platform is a **near-patient testing system** for sepsis management, but it **does not yet have regulatory clearance** for marketing as a diagnostic product in the United States.  **[1704287_6e8edf3b0bee4b42ba2b95cb0b72de87_0]** **[1704287_6e8edf3b0bee4b42ba2b95cb0b72de87_1]**